Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Lackner MR"" wg kryterium: Autor


Tytuł :
Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer.
Autorzy :
Wagle MC; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. .
Castillo J; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Srinivasan S; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Holcomb T; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Yuen KC; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Kadel EE; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Mariathasan S; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Halligan DL; Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.
Carr AR; Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.
Bylesjo M; Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.
McAdam PR; Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.
Lynagh S; Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.
Marien KM; HistoGeneX, Antwerp, Belgium.
Kockx M; HistoGeneX, Antwerp, Belgium.
Waumans Y; HistoGeneX, Antwerp, Belgium.
Huang SA; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Lackner MR; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Mounir Z; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. .
Pokaż więcej
Źródło :
Cancer immunology research [Cancer Immunol Res] 2020 Jul; Vol. 8 (7), pp. 844-850. Date of Electronic Publication: 2020 Apr 22.
Typ publikacji :
Journal Article
MeSH Terms :
Mutation*
Oncogene Fusion*
B7-H1 Antigen/*genetics
Biomarkers, Tumor/*immunology
Lymphocytes, Tumor-Infiltrating/*immunology
Prostatic Neoplasms/*genetics
Prostatic Neoplasms/*immunology
B7-H1 Antigen/immunology ; Biomarkers, Tumor/genetics ; Gene Expression Regulation, Neoplastic ; Humans ; Macrophages/immunology ; Male ; Neoplasm Grading ; Neoplasm Staging ; Prostatic Neoplasms/pathology ; RNA-Seq/methods
Czasopismo naukowe
Tytuł :
Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level.
Autorzy :
Lu S; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California; Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, California.
Chang CJ; Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, California.
Guan Y; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California.
Szafer-Glusman E; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California.
Punnoose E; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California.
Do A; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California.
Suttmann B; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California.
Gagnon R; Division of Expression Analysis Genomics, Q2 Solutions, Morrisville, North Carolina.
Rodriguez A; Department of Translational Research, Epic Sciences Inc., San Diego, California.
Landers M; Department of Translational Research, Epic Sciences Inc., San Diego, California.
Spoerke J; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California.
Lackner MR; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California.
Xiao W; Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, California. Electronic address: .
Wang Y; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California. Electronic address: .
Pokaż więcej
Źródło :
The Journal of molecular diagnostics : JMD [J Mol Diagn] 2020 Jun; Vol. 22 (6), pp. 770-781. Date of Electronic Publication: 2020 Apr 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.
Autorzy :
Moore HM; Oncology Biomarker Development, Genentech Inc., South San Francisco, California.
Savage HM; Oncology Biomarker Development, Genentech Inc., South San Francisco, California.
O'Brien C; IDEAYA Biosciences, South San Francisco, California.
Zhou W; Translational Oncology, Genentech Inc., South San Francisco, California.
Sokol ES; Cancer Genomics Research, Foundation Medicine Inc., Cambridge, Massachusetts.
Goldberg ME; Cancer Genomics Research, Foundation Medicine Inc., Cambridge, Massachusetts.
Metcalfe C; Translational Oncology, Genentech Inc., South San Francisco, California.
Friedman LS; ORIC Pharmaceuticals, South San Francisco, California.
Lackner MR; IDEAYA Biosciences, South San Francisco, California.
Wilson TR; Oncology Biomarker Development, Genentech Inc., South San Francisco, California. .
Pokaż więcej
Źródło :
Molecular cancer therapeutics [Mol Cancer Ther] 2020 Jan; Vol. 19 (1), pp. 292-303. Date of Electronic Publication: 2019 Sep 18.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Biomarkers/*metabolism
Breast Neoplasms/*drug therapy
Imidazoles/*therapeutic use
Oxazepines/*therapeutic use
Antineoplastic Agents/pharmacology ; Breast Neoplasms/pathology ; Cell Line, Tumor ; Female ; Humans ; Imidazoles/pharmacology ; Oxazepines/pharmacology
Czasopismo naukowe
Tytuł :
CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms.
Autorzy :
Castillo J; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California.
Wu E; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California.
Lowe C; Department of Bioanalytical Sciences, Development Sciences, Genentech, Inc., South San Francisco, California.
Srinivasan S; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California.
McCord R; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California.
Wagle MC; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California.
Jayakar S; Department of Research Pathology, Genentech, Inc., South San Francisco, California.
Edick MG; Department of Research Pathology, Genentech, Inc., South San Francisco, California.
Eastham-Anderson J; Department of Research Pathology, Genentech, Inc., South San Francisco, California.
Liu B; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California.
Hutchinson KE; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California.
Jones W; Q Solutions-EA Genomics, Morrisville, North Carolina.
Stokes MP; Cell Signaling Technology, Inc., Danvers, Massachusetts.
Tarighat SS; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California.
Holcomb T; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California.
Glibicky A; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California.
Romero FA; Department of Discovery Chemistry, Genentech, Inc., South San Francisco, California.
Magnuson S; Department of Discovery Chemistry, Genentech, Inc., South San Francisco, California.
Huang SA; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California.
Plaks V; Department of Bioanalytical Sciences, Development Sciences, Genentech, Inc., South San Francisco, California.
Giltnane JM; Department of Research Pathology, Genentech, Inc., South San Francisco, California.
Lackner MR; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California.
Mounir Z; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California. .
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2019 Aug 01; Vol. 79 (15), pp. 3916-3927. Date of Electronic Publication: 2019 Jun 10.
Typ publikacji :
Journal Article
MeSH Terms :
CREB-Binding Protein/*immunology
E1A-Associated p300 Protein/*immunology
Lymphoma, Follicular/*immunology
T-Lymphocytes, Regulatory/*cytology
T-Lymphocytes, Regulatory/*immunology
Acetylation ; CD4-Positive T-Lymphocytes/drug effects ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/metabolism ; CREB-Binding Protein/antagonists & inhibitors ; CREB-Binding Protein/genetics ; Cell Differentiation/physiology ; Down-Regulation ; E1A-Associated p300 Protein/antagonists & inhibitors ; E1A-Associated p300 Protein/genetics ; Histones/metabolism ; Humans ; Lymphoma, Follicular/genetics ; Lymphoma, Follicular/metabolism ; Lymphoma, Follicular/pathology ; Mutation ; Pyrazoles/pharmacology ; Pyridines/pharmacology ; T-Lymphocytes, Regulatory/drug effects ; T-Lymphocytes, Regulatory/metabolism ; Transcription, Genetic ; Transcriptome
Czasopismo naukowe
Tytuł :
A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.
Autorzy :
Piskol R; Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, California. .
Huw L; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. .
Sergin I; Molecular Oncology, Genentech, Inc., South San Francisco, California.
Kljin C; Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, California.
Modrusan Z; Molecular Biology, Genentech, Inc., South San Francisco, California.
Kim D; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Kljavin N; Molecular Oncology, Genentech, Inc., South San Francisco, California.
Tam R; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Patel R; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Burton J; Molecular Oncology, Genentech, Inc., South San Francisco, California.
Penuel E; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Qu X; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Koeppen H; Pathology, Genentech, Inc., South San Francisco, California.
Sumiyoshi T; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
de Sauvage F; Molecular Biology, Genentech, Inc., South San Francisco, California.
Lackner MR; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
de Sousa E Melo F; Discovery Oncology, Genentech, Inc., South San Francisco, California. .
Kabbarah O; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Jul 15; Vol. 25 (14), pp. 4431-4442. Date of Electronic Publication: 2019 Apr 19.
Typ publikacji :
Journal Article
MeSH Terms :
Gene Expression Regulation, Neoplastic*
Mutation*
Biomarkers, Tumor/*genetics
Colorectal Neoplasms/*classification
Colorectal Neoplasms/*genetics
Gene Expression Profiling/*methods
Molecular Typing/*methods
Animals ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Cohort Studies ; Colorectal Neoplasms/secondary ; Female ; Humans ; Mice ; Mice, Inbred NOD ; Neoplasm Metastasis ; Neoplasm Staging ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.
Autorzy :
Chen X; Department of Oncology Biomarker Development, Genentech, South San Francisco, California. .
Chang CW; Department of Biostatistics, Genentech, South San Francisco, California.
Spoerke JM; Department of Oncology Biomarker Development, Genentech, South San Francisco, California.
Yoh KE; Department of Oncology Biomarker Development, Genentech, South San Francisco, California.
Kapoor V; Department of Oncology Biomarker Development, Genentech, South San Francisco, California.
Baudo C; Department of Oncology Biomarker Development, Genentech, South San Francisco, California.
Aimi J; Department of Oncology Biomarker Development, Genentech, South San Francisco, California.
Yu M; Department of Discovery Oncology, Genentech, South San Francisco, California.
Liang-Chu MMY; Department of Discovery Oncology, Genentech, South San Francisco, California.
Suttmann R; Department of Oncology Biomarker Development, Genentech, South San Francisco, California.
Huw LY; Department of Oncology Biomarker Development, Genentech, South San Francisco, California.
Gendreau S; Department of Oncology Biomarker Development, Genentech, South San Francisco, California.
Cummings C; Department of Oncology Biomarker Development, Genentech, South San Francisco, California.
Lackner MR; Department of Oncology Biomarker Development, Genentech, South San Francisco, California. .
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Apr 01; Vol. 25 (7), pp. 2254-2263. Date of Electronic Publication: 2019 Jan 07.
Typ publikacji :
Journal Article
MeSH Terms :
Biomarkers, Tumor*
Circulating Tumor DNA*
Genome, Human*
Genomics*/methods
Carcinoma, Squamous Cell/*genetics
Lung Neoplasms/*genetics
Carcinoma, Squamous Cell/diagnosis ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/mortality ; Cell Line, Tumor ; Cohort Studies ; DNA Copy Number Variations ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; High-Throughput Nucleotide Sequencing ; Humans ; Lung Neoplasms/diagnosis ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality ; Molecular Targeted Therapy ; Polymorphism, Single Nucleotide ; Prognosis ; Sequence Analysis, DNA ; Whole Genome Sequencing
Czasopismo naukowe
Tytuł :
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.
Autorzy :
Joseph JD
Darimont B
Zhou W
Arrazate A
Young A
Ingalla E
Walter K
Blake RA
Nonomiya J
Guan Z
Kategaya L
Govek SP
Lai AG
Kahraman M
Brigham D
Sensintaffar J
Lu N
Shao G
Qian J
Grillot K
Moon M
Prudente R
Bischoff E
Lee KJ
Bonnefous C
Douglas KL
Julien JD
Nagasawa JY
Aparicio A
Kaufman J
Haley B
Giltnane JM
Wertz IE
Lackner MR
Nannini MA
Sampath D
Schwarz L
Manning HC
Tantawy MN
Arteaga CL
Heyman RA
Rix PJ
Friedman L
Smith ND
Metcalfe C
Hager JH
Pokaż więcej
Źródło :
ELife [Elife] 2019 Jan 07; Vol. 8. Date of Electronic Publication: 2019 Jan 07.
Typ publikacji :
Published Erratum
Tytuł :
Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers.
Autorzy :
Wilson TR; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. .
Udyavar AR; Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, California.
Chang CW; Department of Biostatistics, Genentech, Inc., South San Francisco, California.
Spoerke JM; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Aimi J; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Savage HM; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Daemen A; Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, California.
O'Shaughnessy JA; US Oncology, Dallas, Texas.; Baylor University Medical Center, Dallas, Texas.; Texas Oncology, Dallas, Texas.
Bourgon R; Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, California.
Lackner MR; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. .
Pokaż więcej
Źródło :
Molecular cancer research : MCR [Mol Cancer Res] 2019 Jan; Vol. 17 (1), pp. 97-108. Date of Electronic Publication: 2018 Aug 31.
Typ publikacji :
Journal Article
MeSH Terms :
Biomarkers, Tumor/*genetics
Breast Neoplasms/*genetics
Genomics/*methods
Triple Negative Breast Neoplasms/*genetics
Breast Neoplasms/pathology ; Female ; Humans ; Neoplasm Recurrence, Local ; Prognosis
Czasopismo naukowe
Tytuł :
Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology.
Autorzy :
Okrah K; 1Department of Biostatistics, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Tarighat S; 2Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Liu B; 2Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Koeppen H; 3Department of Research Pathology, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Wagle MC; 2Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Cheng G; 2Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Sun C; 2Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Dey A; 4Department of Research, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Chang MT; 4Department of Research, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Sumiyoshi T; 2Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Mounir Z; 2Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Cummings C; 2Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Hampton G; 2Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Amler L; 2Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Fridlyand J; 1Department of Biostatistics, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Hegde PS; 2Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Turley SJ; 4Department of Research, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Lackner MR; 2Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Huang SM; 2Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Pokaż więcej
Źródło :
NPJ precision oncology [NPJ Precis Oncol] 2018 Nov 15; Vol. 2, pp. 25. Date of Electronic Publication: 2018 Nov 15 (Print Publication: 2018).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types.
Autorzy :
Wagle MC; 1Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Kirouac D; 2Department of Pre-Clinical and Translational PKPD, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Klijn C; 3Department of Bioinformatics, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Liu B; 1Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Mahajan S; 1Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Junttila M; 4Department of Translational Oncology, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Moffat J; 5Department of Biochemical and Cellular pharmacology, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Merchant M; 4Department of Translational Oncology, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Huw L; 1Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Wongchenko M; 1Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Okrah K; 6Department of Biostatistics, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Srinivasan S; 1Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Mounir Z; 1Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Sumiyoshi T; 1Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Haverty PM; 3Department of Bioinformatics, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Yauch RL; 4Department of Translational Oncology, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Yan Y; 1Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Kabbarah O; 1Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Hampton G; 1Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Amler L; 1Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Ramanujan S; 2Department of Pre-Clinical and Translational PKPD, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Lackner MR; 1Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
Huang SA; 1Department of Oncology Biomarker Development, Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.; 7Present Address: Bristol-Myers Squibb, 3551 Lawrenceville Princeton, Lawrence Township, NJ 08648 USA.
Pokaż więcej
Źródło :
NPJ precision oncology [NPJ Precis Oncol] 2018 Mar 07; Vol. 2 (1), pp. 7. Date of Electronic Publication: 2018 Mar 07 (Print Publication: 2018).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Autorzy :
Leong S; Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA .
Moss RA; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Bowles DW; Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA.
Ware JA; Genentech, Inc., South San Francisco, California, USA.
Zhou J; Genentech, Inc., South San Francisco, California, USA.
Spoerke JM; Genentech, Inc., South San Francisco, California, USA.
Lackner MR; Genentech, Inc., South San Francisco, California, USA.
Shankar G; Genentech, Inc., South San Francisco, California, USA.
Schutzman JL; Genentech, Inc., South San Francisco, California, USA.
van der Noll R; Division of Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Voest EE; Division of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Schellens JHM; Division of Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2017 Dec; Vol. 22 (12), pp. 1491-1499. Date of Electronic Publication: 2017 Aug 10.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
ErbB Receptors/*genetics
Erlotinib Hydrochloride/*administration & dosage
Indazoles/*administration & dosage
Neoplasms/*drug therapy
Protein Kinase Inhibitors/*administration & dosage
Sulfonamides/*administration & dosage
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Cell Proliferation/genetics ; Dose-Response Relationship, Drug ; ErbB Receptors/antagonists & inhibitors ; Erlotinib Hydrochloride/adverse effects ; Erlotinib Hydrochloride/pharmacokinetics ; Female ; Humans ; Indazoles/adverse effects ; Indazoles/pharmacokinetics ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Staging ; Neoplasms/genetics ; Neoplasms/pathology ; Phosphatidylinositol 3-Kinases/genetics ; Phosphoinositide-3 Kinase Inhibitors ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacokinetics ; Sulfonamides/adverse effects ; Sulfonamides/pharmacokinetics
Czasopismo naukowe
Tytuł :
High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing.
Autorzy :
Guan Y; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Mayba O; Department of Bioinformatics, Genentech, Inc., South San Francisco, California.
Sandmann T; Department of Bioinformatics, Genentech, Inc., South San Francisco, California.
Lu S; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Choi Y; Department of Biostatistics, Genentech, Inc., South San Francisco, California.
Darbonne WC; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Leveque V; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Ryner L; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Humke E; Department of Clinical Science, Genentech, Inc., South San Francisco, California.
Tam NWR; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Sujathasarma S; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Cheung A; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Bourgon R; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Lackner MR; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Wang Y; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. Electronic address: .
Pokaż więcej
Źródło :
The Journal of molecular diagnostics : JMD [J Mol Diagn] 2017 Nov; Vol. 19 (6), pp. 921-932. Date of Electronic Publication: 2017 Sep 01.
Typ publikacji :
Journal Article
MeSH Terms :
Biomarkers, Tumor/*blood
Circulating Tumor DNA/*blood
High-Throughput Nucleotide Sequencing/*methods
Neoplasms/*blood
Humans ; Microfluidics/methods ; Multiplex Polymerase Chain Reaction/methods ; Mutation ; Neoplasms/genetics ; Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.
Autorzy :
Qu X; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Sandmann T; Bioinformatics and Computational Biology, Genentech Inc., South San Francisco, CA, USA.
Frierson H Jr; Department of Pathology, University of Virginia Health System, Charlottesville, VA, USA.
Fu L; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Fuentes E; Department of Pathology, Genentech Inc., South San Francisco, CA, USA.
Walter K; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Okrah K; Department of Biostatistics, Genentech Inc., South San Francisco, CA, USA.
Rumpel C; Department of Pathology, University of Virginia Health System, Charlottesville, VA, USA.
Moskaluk C; Department of Pathology, University of Virginia Health System, Charlottesville, VA, USA.
Lu S; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Wang Y; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Bourgon R; Bioinformatics and Computational Biology, Genentech Inc., South San Francisco, CA, USA.
Penuel E; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Pirzkall A; Department of Clinical Sciences, Genentech Inc., South San Francisco, CA, USA.
Amler L; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Lackner MR; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Tabernero J; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Hampton GM; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Kabbarah O; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Pokaż więcej
Źródło :
Oncogene [Oncogene] 2016 Dec 15; Vol. 35 (50), pp. 6403-6415. Date of Electronic Publication: 2016 Jun 06.
Typ publikacji :
Journal Article
MeSH Terms :
DNA Methylation*
Promoter Regions, Genetic*
Colorectal Neoplasms/*genetics
Epiregulin/*genetics
ErbB Receptors/*physiology
Azacitidine/analogs & derivatives ; Azacitidine/pharmacology ; Cell Line, Tumor ; Colorectal Neoplasms/drug therapy ; Decitabine ; Disease Progression ; ErbB Receptors/antagonists & inhibitors ; Humans ; Phosphorylation
Czasopismo naukowe
Tytuł :
The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy.
Autorzy :
Cummings CA; Oncology Biomarker Development, Genentech, Inc, South San Francisco, California, USA.
Peters E; Oncology Biomarker Development, Genentech, Inc, South San Francisco, California, USA.
Lacroix L; Department of Biology and Pathology, Translational Research Unit, Gustave Roussy Cancer Center, Villejuif, France.
Andre F; Department of Medical Oncology, Université Paris Sud, Gustave Roussy Cancer Center, INSERM U981, Villejuif, France.
Lackner MR; Oncology Biomarker Development, Genentech, Inc, South San Francisco, California, USA.
Pokaż więcej
Źródło :
Clinical and translational science [Clin Transl Sci] 2016 Dec; Vol. 9 (6), pp. 283-292. Date of Electronic Publication: 2016 Nov 15.
Typ publikacji :
Journal Article
MeSH Terms :
High-Throughput Nucleotide Sequencing*
Medical Oncology*
Precision Medicine*
Humans ; Neoplasms/therapy
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies